Sartorius partners with Sensible Biotechnologies to enhance mRNA production capabilities globally.
Jul 09, 2025•9 days ago
Contract Type
partnership
Description
Sartorius Stedim Biotech and Sensible Biotechnologies have signed a Memorandum of Understanding to scale up Sensible's cell-based mRNA design platform. The partnership aims to enable clinical-grade production of mRNA by 2026 and expand production facilities from Slovakia to the US, UK, and Europe.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months